Taysha Gene Therapies Inc... (TSHA)

NASDAQ: TSHA · Real-Time Price · USD

2.42

0.48 (24.74%)

At close: May 01, 2025, 3:59 PM

2.39

-1.00%

After-hours: May 01, 2025, 06:11 PM EDT

24.74% (1D)

Bid	2.39
Market Cap	495.21M
Revenue (ttm)	8.33M
Net Income (ttm)	-89.3M
EPS (ttm)	-0.36
PE Ratio (ttm)	-6.71
Forward PE	-4.41
Analyst	Buy

Ask	2.48
Volume	6,167,476
Avg. Volume (20D)	2,281,440.3
Open	1.96
Previous Close	1.94
Day's Range	1.93 - 2.43
52-Week Range	1.05 - 4.32
Beta	0.94

About TSHA

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 24, 2020

Employees 73

Stock Exchange NASDAQ

Ticker Symbol TSHA

Website https://www.tayshagtx.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for TSHA stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 189.86% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

+2.71%

Taysha Gene Therapies shares are trading higher. C... Unlock content with Pro Subscription

5 months ago

+46.63%

Taysha Gene Therapies shares are trading higher. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.

News

1 month ago · nypost.com

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...

2 months ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director & Head of Investor Relations Sean Nolan - Chie...

2 months ago · zacks.com

Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.35 per share a year ago.